Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 6/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30193791 | 0.87 | NLRP3 (0.51) | NLRP3POLBTHRBTP53MAPT | |
| SCHEMBL21677367 | 0.82 | NLRP3 (0.57) | NLRP3POLBTHRBHSD17B10KDM4E | |
| SCHEMBL25771182 | 0.81 | NLRP3 (0.45) | NLRP3POLBTHRBHSD17B10TP53 | |
| SCHEMBL30193839 | 0.80 | NLRP3 (0.44) | NLRP3POLBTHRBHSD17B10TP53 | |
| SCHEMBL25771179 | 0.78 | NLRP3 (0.41) | NLRP3POLBTHRBMAPT | |
| SCHEMBL21677214 | 0.77 | NLRP3 (0.62) | NLRP3POLBTHRBTP53 | |
| SCHEMBL23930389 | 0.77 | KDM4E (0.45) | NLRP3POLBTHRBHSD17B10KDM4E | |
| SCHEMBL25241917 | 0.76 | KDM4E (0.46) | NLRP3POLBTHRBHSD17B10KDM4E | |
| SCHEMBL23881933 | 0.75 | NLRP3 (0.61) | NLRP3POLBTHRBKDM4ETP53 | |
| SCHEMBL25771199 | 0.74 | KDM4E (0.44) | NLRP3POLBTHRBHSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240391932-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2024-11-28 | — | — | US | disclosed |
| EP-4401739-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | Nico Therapeutics, Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| WO-2023044043-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. (US) | 2023-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240391932-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | NLRP3, NLRP1, NOD1 | NLRP3 1/4885POLB 3737/4885THRB 3774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.